30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased
16.7.2025 09:15:00 CEST | Business Wire | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life.
Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health.
The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein.
This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily intake of spermidine. Spermidine is associated with benefits to longevity, cardiovascular health and brain health.
The paper states that “during (Almased’s) proteolytic enzyme procedure, bioactive and biogenic peptides, which were not detectable before in the raw materials, naturally occur. It can be assumed that the production process is significant in producing bioactive compounds responsible for unexpected positive effects on the metabolism, even in people who are not overweight”.
Other key findings in the 2022 review in Heliyon have shown:
- 167% increase in GLP-1 production and a 358% increase in PYY production (a satiety-induced hormone produced in the intestine) compared to consuming a standard American diet containing the same amount of calories by the same individuals (Oliveira et al. 2022)
- Almased group lost 145% more weight than the control group (-13lbs vs. -5.3lbs) in 12 weeks. Fat loss was 181% more in the Almased group (-9.9 lbs) than in the control group (-3.52 lbs) over the same period of time despite comparable weights before the study (Röhling et al. 2020)
- Almased plus resistance training increased muscle strength by 33% versus resistance training alone (Deibert et al 2010)
- Waist circumference reduction 239% greater in the Almased group compared to a fat-reduced diet (2.4in vs. 0.7in) after 6 weeks. Fat mass loss was 82% greater in the Almased group compared to a fat-reduced diet (11.2lbs vs. 6.1lbs) after 6 weeks (König et al 2008)
- A study on post-menopausal women saw a 62% reduction in the prevalence of metabolic syndrome and significant fat loss without losing lean mass (Deibert et al. 2007)
- Almased reduced liver fat content by an average of 56% and supports a healthy inflammatory response (Deibert et al 2019)
- Almased preserved 100% muscle mass while losing weight (Deibert et al 2004)
Researchers found that Almased improves the fat burning process so you burn fat and calories more effectively (Oliveira et al 2021). In overweight and obese individuals, Almased meal replacement regimens resulted in greater reductions in body weight, body mass index (BMI), and fat mass compared to traditional low-calorie diets, while also improving glycemic control and lipid profiles.
Beyond weight management, the review highlights Almased’s role in supporting healthy blood sugar levels in both prediabetic and type 2 diabetic individuals. This indicates Almased is safe for people with diabetes.
The review also notes Almased’s unique anti-aging and wellness benefits. Regular use has been linked to healthy cell function, reduced stress markers, and better overall energy and mood. Almased’s protein-rich formula, containing essential amino acids and bioactive peptides, supports muscle preservation, cellular health, and supports a healthy inflammatory response, contributing to improved quality of life and longevity.
“The results presented underscore the efficacy of the soy-yogurt-honey formula (Almased) in weight management and the improvement of obesity-associated cardiovascular disease and metabolic risk factors.” said the study’s authors.
About Almased
Founded over 30 years ago in Germany by holistic therapist Hubertus Trouillé, and his son Andre Trouillé, Almased is a family-owned and operated company dedicated to promoting health and wellness worldwide. Recognized as Europe’s #1 science backed weight-loss meal replacement shake brand, Almased combines natural ingredients with a patented fermentation process to deliver high-quality, effective nutrition. With over 30 peer reviewed studies across 3 decades, Almased is a global leader in metabolic health. With a commitment to sourcing the highest quality ingredients in the world, Almased continues its mission to help people achieve healthier, happier lives with clean, sustainable products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250716374177/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength25.8.2026 00:40:00 CEST | Press release
Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-endOmlyclo® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentationsMultiple dose strengths and device options broaden treatment flexibility for healthcare professionals Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other
Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release
QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom